Pascal Prigent, Genfit CEO
Ipsen fronts $136M to bag Genfit's once-failed NASH drug, betting on its potential in rare liver condition
Somebody believes in elafibranor after all.
The drug, which had been considered a bright prospect in the failure-prone but highly lucrative race to treat non-alcoholic steatohepatitis, imploded after it failed a closely watched trial, forcing its developer, Genfit, to throw in the towel. But after a lonely year steering past the wreckage — chopping nearly half of its workforce in a painful restructuring — Genfit has found a trusting partner in fellow French drugmaker Ipsen.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters